Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Lupus Nephritis

Belimumab (Lupus Nephritis)

Brand names: Benlysta

This entry covers belimumab for lupus nephritis, a monoclonal antibody against B-lymphocyte stimulator (BLyS) used as add-on therapy to standard immunosuppression in active lupus nephritis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds and neutralises soluble BLyS (BAFF), reducing survival of autoreactive B cells and lowering autoantibody production that drives systemic lupus erythematosus and renal involvement.

Prescribing in practice

  • Serious and opportunistic infections can occur; do not start during active severe infection, and screen and manage hepatitis B reactivation risk before treatment.
  • It is an adjunct to background therapy in lupus nephritis, not a replacement, and serious hypersensitivity or infusion reactions can occur with the intravenous form.
  • Avoid live vaccines during treatment, and report any new neuropsychiatric symptoms given reports of depression and rare PML.

Monitoring

Monitor for infection and infusion or injection-site reactions, and review renal response and mental health during treatment.

Counselling the patient

  • Tell any clinician you are on immune-suppressing treatment and report signs of infection promptly.
  • Report new or worsening low mood or thoughts of self-harm.
  • Avoid live vaccines unless advised by your specialist.

Evidence & guidelines

Belimumab as add-on therapy for active lupus nephritis is supported by the BLISS-LN trial and recommended by NICE.

Reference: BLISS-LN Trial (Furie et al. NEJM 2020); MHRA DSU 2016 (Depression/Suicide); NICE TA397; SPC Benlysta; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways